Mitsubishi UFJ Trust & Banking Corp lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 0.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 430,091 shares of the medical research company’s stock after selling 2,536 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.20% of Edwards Lifesciences Corporation worth $50,854,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in Edwards Lifesciences Corporation by 14.9% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 49,959 shares of the medical research company’s stock worth $5,907,000 after buying an additional 6,492 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in Edwards Lifesciences Corporation by 2.8% in the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 2,776 shares of the medical research company’s stock worth $320,000 after buying an additional 76 shares in the last quarter. Penserra Capital Management LLC raised its stake in Edwards Lifesciences Corporation by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,664 shares of the medical research company’s stock worth $196,000 after buying an additional 192 shares in the last quarter. Intrust Bank NA raised its stake in Edwards Lifesciences Corporation by 12.2% in the second quarter. Intrust Bank NA now owns 6,263 shares of the medical research company’s stock worth $741,000 after buying an additional 679 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Edwards Lifesciences Corporation by 1.6% in the second quarter. American Century Companies Inc. now owns 2,079,309 shares of the medical research company’s stock worth $245,857,000 after buying an additional 32,434 shares in the last quarter. 82.36% of the stock is currently owned by institutional investors.

Edwards Lifesciences Corporation (NYSE EW) opened at 113.11 on Tuesday. The firm has a market cap of $23.88 billion, a PE ratio of 34.31 and a beta of 0.63. The stock’s 50 day moving average price is $115.76 and its 200-day moving average price is $106.74. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The business had revenue of $842 million during the quarter, compared to the consensus estimate of $839.16 million. During the same quarter in the prior year, the firm earned $0.76 EPS. The business’s revenue was up 10.9% on a year-over-year basis. Equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

WARNING: This news story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/29/edwards-lifesciences-corporation-ew-stake-reduced-by-mitsubishi-ufj-trust-banking-corp.html.

A number of equities research analysts have recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences Corporation in a research report on Monday. BidaskClub lowered Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research report on Friday. Canaccord Genuity reaffirmed a “buy” rating and set a $155.00 price target (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Royal Bank Of Canada reissued a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Finally, Cowen and Company reissued an “outperform” rating and issued a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Six research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $120.18.

In related news, VP Patrick B. Verguet sold 10,000 shares of the stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $114.88, for a total value of $1,148,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total transaction of $3,883,845.00. The disclosure for this sale can be found here. Insiders have sold a total of 149,281 shares of company stock valued at $17,331,446 in the last three months. Insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.